A Registry-Based Perspective of Interventional Clinical Trials for Duchenne Muscular Dystrophy

{"Background":[0],"and":[1,30,53,76,90,116,149,182,211,270,293,303],"objective":[2],"Duchenne":[3],"muscular":[4,113],"dystrophy":[5],"(DMD)":[6],"is":[7],"a":[8,133,283],"severe,":[9],"progressive,":[10],"X-linked":[11],"genetic":[12,304],"disorder":[13],"caused":[14],"by":[15,123],"pathogenic":[16],"variants":[17],"in":[18,69,80,188,248],"the":[19,44,109,118,159,185,194,205,214,249,254],"dystrophin":[20],"gene,":[21],"leading":[22],"to":[23,62,77],"progressive":[24],"muscle":[25],"weakness,":[26],"loss":[27],"of":[28,41,47,72,166,232,310,318],"ambulation,":[29],"premature":[31],"mortality.":[32],"Clinical":[33],"trials":[34,67,131,180,228,234],"are":[35,299],"essential":[36],"for":[37,178,226],"advancing":[38],"evidence-based":[39],"management":[40],"DMD;":[42],"however,":[43,314],"overall":[45],"patterns":[46,79],"study":[48,60,81,99,139],"design,":[49,82,140],"intervention":[50,83,141,198],"strategies,":[51],"funding,":[52,87],"results":[54,88,147,327],"reporting":[55],"remain":[56],"incompletely":[57],"characterized.":[58],"This":[59],"aimed":[61],"characterize":[63],"interventional":[64,130,168],"DMD":[65,169,286],"clinical":[66],"registered":[68,312],"ClinicalTrials.gov":[70,225,280],"as":[71],"May":[73],"25,":[74],"2026,":[75],"assess":[78],"type,":[84,142],"trial":[85,91,124,143,170],"phase,":[86,144],"reporting,":[89],"start":[92,125,150],"era.":[93],"Methods":[94],"A":[95,164],"retrospective":[96],"registry-based":[97],"descriptive":[98],"was":[100,120,176,184,204,213,257],"conducted":[101],"using":[102,108,158],"ClinicalTrials.gov.":[103],"DMD-related":[104],"records":[105,128,171,281],"were":[106,129,152,156,172,193,222,321],"identified":[107],"free-text":[110],"terms":[111],"\\"Duchenne":[112],"dystrophy,\\"":[114],"\\"Duchenne,\\"":[115],"\\"DMD\\";":[117],"search":[119],"not":[121,258,274,322],"restricted":[122],"year.":[126],"Eligible":[127],"with":[132,289,301],"DMD-specific":[134],"objective.":[135],"Trial-level":[136],"eligibility":[137,175],"characteristics,":[138],"funding":[145],"source,":[146],"posting,":[148],"year":[151],"summarized.":[153],"Era-wise":[154],"comparisons":[155,317],"performed":[157],"Fisher-Freeman-Halton":[160],"exact":[161],"test.":[162],"Results":[163,221],"total":[165],"232":[167],"included.":[173],"Male-only":[174],"recorded":[177],"198/232":[179],"(85.3%),":[181],"treatment":[183],"primary":[186],"purpose":[187],"179/232":[189],"(77.2%).":[190],"Drug":[191],"interventions":[192,243],"most":[195,215,250,315],"frequent":[196,294],"coded":[197],"category":[199,208],"(101/232;":[200],"43.5%),":[201],"Phase":[202,266],"2":[203],"largest":[206],"phase":[207],"(58/232;":[209],"25.0%),":[210],"industry":[212,264,291],"common":[216],"funder":[217],"class":[218],"(118/232;":[219],"50.9%).":[220],"posted":[223],"on":[224],"76/232":[227],"(32.8%).":[229],"The":[230],"proportion":[231],"drug-intervention":[233],"differed":[235],"across":[236,277],"start-year":[237],"eras":[238],"(p":[239,261],"=":[240,262],"0.002).":[241],"Biological":[242],"showed":[244],"numerically":[245],"greater":[246],"representation":[247],"recent":[251,311],"era,":[252],"but":[253],"era-wise":[255],"difference":[256],"statistically":[259,323],"significant":[260],"0.420);":[263],"sponsorship,":[265],"3/4":[267],"status,":[268],"randomization,":[269],"masking":[271],"also":[272],"did":[273],"differ":[275],"significantly":[276],"eras.":[278],"Conclusions":[279],"show":[282],"predominantly":[284],"treatment-oriented":[285],"research":[287],"profile,":[288],"substantial":[290],"involvement":[292],"small-cohort":[295],"studies.":[296],"Therapeutic":[297],"modalities":[298],"diverse,":[300],"biological":[302],"approaches":[305],"representing":[306],"an":[307,330],"important":[308,331],"share":[309],"activity;":[313],"temporal":[316],"trial-design":[319],"characteristics":[320],"significant.":[324],"Limited":[325],"registry":[326],"posting":[328],"remains":[329],"gap.":[332]}